What is X4 Pharmaceuticals, Inc. (XFOR)?

X4 Pharmaceuticals, Inc. (XFOR) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of XFOR?

The current price of XFOR is $3.35. Prices are updated in real time on Stocks360.

What is XFOR's price-to-earnings (PE) ratio?

XFOR's trailing twelve-month PE ratio is -2.79, based on current price and earnings per share data available on Stocks360.

What is XFOR's market capitalization?

XFOR's market capitalization is $332,141,445.00, placing it in the small-cap tier.

X4 Pharmaceuticals, Inc. (XFOR)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.35

Market Cap

$332.14M

PE (TTM)

-2.79

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.35

Day Range

$3.19 – $3.40

52-wk Range

$2.43 – $4.83

Avg Volume

N/A

Volume

706.23K

X4 Pharmaceuticals, Inc. (XFOR) is a publicly traded company in the Healthcare sector. Latest price: $3.35. Market cap $332.14M. Trailing PE -2.79. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $4.04 2026-10-30 · $3.35 (-17.08%)

Earnings

Most Recent

Aug 7, 2026

EPS $-0.13 vs est. $-0.18

Beat by $0.05

Next Earnings

Nov 4, 2026

EPS estimate $-0.18

Proprietary Signals

Signal snapshot temporarily unavailable.

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical app…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.79×
P/S (TTM)	20.96×
P/B	2.72×
P/FCF (TTM)	-3.97×
EV / EBITDA	-2.69×
EV / Sales	13.52×
Earnings Yield	-21.30%
Free Cash Flow Yield	-25.21%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$214.27M
Revenue (TTM)	$15.85M
Net Income (TTM)	-$70.73M
Free Cash Flow (TTM)	-$75.00M
Net Debt	-$117.87M
Working Capital	$199.49M
Gross Margin	81.22%
Operating Margin	-554.71%
Net Margin	-568.80%
Return on Equity	-63.05%
Return on Invested Capital	-37.53%